Payment overview · 2025
General Payments
$256.48
9 reported records · 4 companies
Healthcare provider profile · identity verified
Melin J Moses, MD
Allopathic & Osteopathic Physicians|Family Medicine · HUNTINGTON, WV · NPI 1104825512
Verified facts
What the public records show
CMS Open Payments records show Melin J Moses, MD received $256.48 in general payments during 2025 across 9 reported records.
Novo Nordisk Inc accounted for 67.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Synthroid by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 95 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $173.77 | 67.8% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $46.20 | 18.0% | 2 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $22.19 | 8.7% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $14.32 | 5.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $224.21 | 8 |
| Education | $32.27 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $124.47 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $46.20 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $46.20 | 2 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $22.19 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $17.03 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $17.03 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $14.32 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $14.32 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 78 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 95 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
56 | 15 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
95 | 19 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
78 | 24 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Alprazolam | Alprazolam | 467 | 78 |
| Levothyroxine Sodium | Levothyroxine Sodium | 436 | 124 |
| Lisinopril | Lisinopril | 331 | 93 |
| Amlodipine Besylate | Amlodipine Besylate | 322 | 91 |
| Gabapentin | Gabapentin | 310 | 56 |
| Omeprazole | Omeprazole | 274 | 83 |
| Metoprolol Succinate | Metoprolol Succinate | 252 | 74 |
| Prednisone | Prednisone | 250 | 137 |
| Atorvastatin Calcium | Atorvastatin Calcium | 247 | 77 |
| Losartan Potassium | Losartan Potassium | 234 | 62 |
| Tamsulosin Hcl | Tamsulosin Hcl | 189 | 54 |
| Cefdinir | Cefdinir | 186 | 144 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 171 | 24 |
| Meloxicam | Meloxicam | 171 | 47 |
| Duloxetine Hcl | Duloxetine Hcl | 158 | 45 |
| Pantoprazole Sodium | Pantoprazole Sodium | 151 | 49 |
| Simvastatin | Simvastatin | 147 | 40 |
| Hydrochlorothiazide | Hydrochlorothiazide | 141 | 35 |
| Clopidogrel | Clopidogrel Bisulfate | 138 | 43 |
| Fluoxetine Hcl | Fluoxetine Hcl | 136 | 42 |
| Sertraline Hcl | Sertraline Hcl | 136 | 38 |
| Tramadol Hcl | Tramadol Hcl | 136 | 26 |
| Zolpidem Tartrate | Zolpidem Tartrate | 130 | 24 |
| Potassium Chloride | Potassium Chloride | 126 | 36 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 120 | 18 |
| Furosemide | Furosemide | 118 | 39 |
| Azithromycin | Azithromycin | 111 | 91 |
| Metformin Hcl | Metformin Hcl | 109 | 33 |
| Montelukast Sodium | Montelukast Sodium | 106 | 34 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 105 | 33 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 104 | 35 |
| Metoprolol Tartrate | Metoprolol Tartrate | 98 | 30 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 96 | 30 |
| Ozempic | Semaglutide | 95 | 19 |
| Glipizide Er | Glipizide | 91 | 24 |
| Famotidine | Famotidine | 81 | 25 |
| Escitalopram Oxalate | Escitalopram Oxalate | 79 | 23 |
| Eliquis | Apixaban | 78 | 24 |
| Clonazepam | Clonazepam | 75 | 14 |
| Donepezil Hcl | Donepezil Hcl | 75 | 21 |
| Glipizide | Glipizide | 70 | 22 |
| Ondansetron Hcl | Ondansetron Hcl | 70 | 22 |
| Fluticasone Propionate | Fluticasone Propionate | 68 | 32 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 68 | 18 |
| Metformin Hcl Er | Metformin Hcl | 68 | 19 |
| Allopurinol | Allopurinol | 63 | 18 |
| Citalopram Hbr | Citalopram Hydrobromide | 63 | 19 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 63 | 20 |
| Ibuprofen | Ibuprofen | 61 | 22 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 60 | 19 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 58 | 42 |
| Synthroid | Levothyroxine Sodium | 56 | 15 |
| Diazepam | Diazepam | 53 | 12 |
| Enalapril Maleate | Enalapril Maleate | 53 | 13 |
| Temazepam | Temazepam | 52 | suppressed |
| Carvedilol | Carvedilol | 48 | 16 |
| Mounjaro | Tirzepatide | 48 | suppressed |
| Pregabalin | Pregabalin | 45 | suppressed |
| Spironolactone | Spironolactone | 45 | 17 |
| Hydralazine Hcl | Hydralazine Hcl | 44 | 15 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 44 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 43 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 43 | 13 |
| Buspirone Hcl | Buspirone Hcl | 40 | 14 |
| Trazodone Hcl | Trazodone Hcl | 40 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 40 | 15 |
| Testosterone Cypionate | Testosterone Cypionate | 38 | 13 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 37 | 15 |
| Lorazepam | Lorazepam | 36 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 36 | 15 |
| Xarelto | Rivaroxaban | 36 | suppressed |
| Bupropion Xl | Bupropion Hcl | 32 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 31 | 21 |
| Atenolol | Atenolol | 30 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 30 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 30 | suppressed |
| Zaleplon | Zaleplon | 30 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 29 | 13 |
| Levetiracetam | Levetiracetam | 29 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 29 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 28 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 28 | 21 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 28 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 27 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 27 | 13 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 26 | suppressed |
| Fluconazole | Fluconazole | 26 | 17 |
| Nifedipine Er | Nifedipine | 26 | suppressed |
| Topiramate | Topiramate | 26 | suppressed |
| Valsartan | Valsartan | 26 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 25 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 24 | suppressed |
| Celecoxib | Celecoxib | 23 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 23 | suppressed |
| Methocarbamol | Methocarbamol | 23 | 14 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 23 | 12 |
| Warfarin Sodium | Warfarin Sodium | 23 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 22 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 22 | suppressed |
| Novolog Flexpen | Insulin Aspart | 22 | suppressed |
| Ondansetron Odt | Ondansetron | 22 | 18 |
| Propranolol Hcl | Propranolol Hcl | 22 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 21 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 21 | suppressed |
| Bumetanide | Bumetanide | 20 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 20 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 20 | suppressed |
| Folic Acid | Folic Acid | 20 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 20 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 19 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 19 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 19 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 18 | 17 |
| Methadone Hcl | Methadone Hcl | 18 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Naproxen | Naproxen | 18 | 12 |
| Amoxicillin | Amoxicillin | 17 | 13 |
| Klor-Con M10 | Potassium Chloride | 17 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 17 | suppressed |
| Torsemide | Torsemide | 17 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 16 | suppressed |
| Digoxin | Digoxin | 15 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Brilinta | Ticagrelor | 14 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 14 | suppressed |
| Ezetimibe | Ezetimibe | 14 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 13 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 13 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 13 | suppressed |
| Insulin Lispro | Insulin Lispro | 13 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 13 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 13 | suppressed |
| Klor-Con M20 | Potassium Chloride | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 13 | suppressed |
| Ramipril | Ramipril | 13 | suppressed |
| Baclofen | Baclofen | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Fentanyl | Fentanyl | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Levemir Flexpen | Insulin Detemir | 12 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 12 | suppressed |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 11 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Glyburide | Glyburide | 11 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 11 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $256.48 · 9 records | Novo Nordisk Inc | AUSTEDO XR, ELIQUIS, NURTEC ODT, Ozempic, QULIPTA, Rybelsus, UBRELVY, Wegovy | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error